Comparing enGene (ENGN) and Its Rivals

enGene (NASDAQ:ENGN) is one of 670 publicly-traded companies in the “Holding & other investment offices” industry, but how does it contrast to its competitors? We will compare enGene to similar businesses based on the strength of its profitability, analyst recommendations, valuation, earnings, risk, institutional ownership and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for enGene and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0	0	6	0	3.00
enGene Competitors	127	574	871	15	2.49

enGene currently has a consensus price target of $34.40, indicating a potential upside of 356.23%. As a group, “Holding & other investment offices” companies have a potential upside of 55.10%. Given enGene’s stronger consensus rating and higher probable upside, research analysts clearly believe enGene is more favorable than its competitors.

Volatility and Risk

enGene has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500. Comparatively, enGene’s competitors have a beta of 0.05, indicating that their average share price is 95% less volatile than the S&P 500.

Institutional and Insider Ownership

64.2% of enGene shares are held by institutional investors. Comparatively, 54.1% of shares of all “Holding & other investment offices” companies are held by institutional investors. 13.7% of enGene shares are held by company insiders. Comparatively, 25.8% of shares of all “Holding & other investment offices” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares enGene and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-63.25%	-5.65%
enGene Competitors	-20.12%	-42.65%	-0.79%

Earnings and Valuation

This table compares enGene and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
enGene	N/A	$104.74 million	-4.79
enGene Competitors	$907.68 million	$69.98 million	39.47

enGene’s competitors have higher revenue, but lower earnings than enGene. enGene is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

enGene competitors beat enGene on 7 of the 13 factors compared.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.